BioRestorative up on license rights agreement for spinal disease therapy

Biorestorative Therapies

05/12/2022 14:20

** Shares of stem cell therapy developer BioRestorative
Therapies Inc  BRTX.O  up 1.7% at $3.70 premarket
    ** Co reports an exclusive license rights agreement with
Regenexx LLC for the development and commercialization of
BRTX-100, its spinal disease therapy 
    ** BRTX-100, currently in the mid-stage, is intended to
treat chronic lumbar disc disease using patient's own bone
marrow cells
    ** Lumbar disc disease can occur due to issues in a spinal
disc in the lower back area, and can cause lower back pain, leg
pain and weakness
    ** As of last close, stock down 15.3% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))